# =============================================================================
# PORTFOLIO HISTORY - Closed Positions Track Record
# =============================================================================
# Purpose: Track all closed positions for performance evaluation
# Updated: After each SELL that closes a position
# Schema: entry/exit dates, prices, P&L, thesis accuracy assessment
# =============================================================================

# Metadata
metadata:
  created: 2026-02-03
  last_updated: 2026-02-11
  total_closed: 12
  total_pnl_eur: -90.85  # Previous -119.85 + IMB.L +29 = ~-90.85
  win_rate: 41.7  # 5 winners / 12 positions (IMB.L is winner +6.9%)
  avg_holding_days: 6

# ADVERSARIAL FV ACCURACY TRACKING (added Session 53 per Devil's Advocate)
# Purpose: Track whether adversarial FVs are accurate or systematically pessimistic
# Check prices at 3mo, 6mo, 12mo after sale. Compare thesis FV vs adversarial FV vs market.
adversarial_fv_tracking:
  next_check: 2026-05-11  # 3 months from today
  positions_to_track:
    - { ticker: A2A.MI, sold: 2026-02-08, exit_price_eur: 2.54, thesis_fv: 2.70, adversarial_fv: 2.04, check_3mo: null, check_6mo: null, check_12mo: null }
    - { ticker: VNA.DE, sold: 2026-02-08, exit_price_eur: 24.78, thesis_fv: 32.58, adversarial_fv: 24.35, check_3mo: null, check_6mo: null, check_12mo: null }
    - { ticker: TATE.L, sold: 2026-02-08, exit_price_gbp: 393.60, thesis_fv: 551, adversarial_fv: 329, check_3mo: null, check_6mo: null, check_12mo: null }
    - { ticker: SAN.PA, sold: 2026-02-09, exit_price_eur: 80.29, thesis_fv: 122, adversarial_fv: 78.69, check_3mo: null, check_6mo: null, check_12mo: null }
    - { ticker: HRB, sold: 2026-02-09, exit_price_usd: 32.77, thesis_fv: 59.58, adversarial_fv: 33.94, check_3mo: null, check_6mo: null, check_12mo: null }
    - { ticker: IMB.L, sold: 2026-02-09, exit_price_gbp: 2472.5, thesis_fv: 3701, adversarial_fv: 3409, check_3mo: null, check_6mo: null, check_12mo: null }
  note: "If market price >> adversarial FV at 12mo for majority, adversarial is too pessimistic. If market price near or below adversarial FV, sells were correct."

# Closed Positions
closed_positions:
  # Template for each closed position:
  # - ticker: SYMBOL
  #   name: "Company Name"
  #   entry_date: YYYY-MM-DD
  #   exit_date: YYYY-MM-DD
  #   shares: N
  #   entry_price: X.XX
  #   exit_price: X.XX
  #   entry_currency: EUR/USD/GBp
  #   invested: X.XX  # Total amount invested (local currency)
  #   proceeds: X.XX  # Total amount received (local currency)
  #   pnl_amount: X.XX  # Profit/Loss amount
  #   pnl_percent: X.XX  # Profit/Loss %
  #   holding_days: N
  #   thesis_fv_at_entry: X.XX  # Fair value from thesis at entry
  #   fv_reached: true/false  # Did price reach 80%+ of FV?
  #   thesis_accuracy:
  #     correct: true/false  # Was the thesis correct in hindsight?
  #     notes: "Brief assessment"
  #   exit_reason: "sell_at_fv|stop_loss|thesis_invalidated|rebalance|error"

  - ticker: ENEL.MI
    name: "Enel S.p.A."
    entry_date: 2026-01-27
    exit_date: 2026-01-31
    shares: 81
    entry_price: 9.225
    exit_price: 9.225
    entry_currency: EUR
    invested_eur: 747.00
    proceeds_eur: 747.00
    pnl_amount: 0.00
    pnl_percent: 0.0
    holding_days: 4
    thesis_fv_at_entry: null  # No formal thesis was written
    fv_reached: false
    thesis_accuracy:
      correct: null  # Position closed before thesis could be validated
      notes: "Sold because bought at fair value without margin of safety (error in process). No loss, but opportunity cost. Recognized process failure and corrected."
    exit_reason: error  # Bought without proper thesis/MoS

  - ticker: SHEL.L
    name: "Shell plc"
    entry_date: 2026-01-26
    exit_date: 2026-02-06
    shares: 10.848578  # Final position after 2 trims (40.8 -> 20.85 -> 10.85)
    entry_price_gbp: 2689  # Original avg cost
    exit_price_gbp: 2774.50
    entry_currency: GBp
    invested_eur: 338  # Prorated invested for remaining 10.85 shares
    proceeds_eur: 346
    pnl_amount_eur: 8
    pnl_percent: 2.3
    holding_days: 11
    thesis_fv_at_entry: 3200  # GBp - original thesis
    thesis_fv_v2: 2680  # GBp - v2.0 re-evaluation
    fv_reached: false
    quality_score: 36  # Borderline Tier C/D
    thesis_accuracy:
      correct: false
      notes: "Original thesis overestimated FV using P/FCF without mid-cycle adjustment. v2.0 re-evaluation showed stock was fairly valued (MoS -3.5%). QS 36 = borderline Tier C/D. Capital better deployed in Tier A compounders. EXIT Protocol 6/6 gates -> SELL. Small gain (+2.3%) despite thesis being wrong on upside."
    exit_reason: thesis_invalidated  # Quality too low + no MoS + better opportunity (AUTO.L)
    lesson_learned: "For cyclicals, EV/EBIT mid-cycle is the correct valuation method, not P/FCF. QS 36 is borderline - capital should be in Tier A/B. EXIT Protocol works: systematic evaluation led to correct rotation decision."

  - ticker: FUTR.L
    name: "Future plc"
    entry_date: 2026-02-03
    exit_date: 2026-02-04
    shares: 111
    entry_price_gbp: 536.40  # Weighted avg: (47*532 + 64*539.5)/111
    exit_price_gbp: 522.50
    entry_currency: GBp
    invested_eur: 695.05  # $817.40 / 1.1762 (avg FX)
    proceeds_eur: 672.20
    pnl_amount_eur: -22.85
    pnl_percent: -2.8
    holding_days: 1
    thesis_fv_at_entry: 1100  # GBp - original thesis
    thesis_fv_v2: 1050  # GBp - v2.0 re-evaluation
    fv_reached: false
    quality_score: 32  # Tier D - reason for exit
    thesis_accuracy:
      correct: null  # Position closed before thesis could be validated
      notes: "Framework v3.0 Tier D violation. QS 32/100 = DO NOT HOLD. Value trap 4/10 factors (secular decline, tech disruption, ROIC<WACC, high goodwill). MoS was 46-53% but quality insufficient. Disciplined exit to redeploy capital to Tier A/B compounders."
    exit_reason: thesis_invalidated  # Framework v3.0 upgrade revealed quality issue
    lesson_learned: "v2.0 portfolio built on P/E+yield screening missed quality dimension. Framework v3.0 Quality Score is essential filter BEFORE valuation."

  - ticker: TEP.PA
    name: "Teleperformance SE"
    entry_date: 2026-01-31
    exit_date: 2026-02-07
    shares: 11.015018
    entry_price_eur: 65.88  # Avg cost
    exit_price_eur: 52.18
    entry_currency: EUR
    invested_eur: 623  # ~725.79 USD / 1.165
    proceeds_eur: 575
    pnl_amount_eur: -48
    pnl_percent: -6.7
    holding_days: 7
    thesis_fv_at_entry: 115  # EUR - original thesis
    thesis_fv_v2: 110  # EUR - v2.0 re-evaluation
    fv_reached: false
    quality_score: 46  # Tier C
    thesis_accuracy:
      correct: null  # Exited before thesis could play out (18-24 month horizon)
      notes: "Capital rotation decision. QS 46 Tier C with ROIC < WACC. MoS was high (38-51%) but revised down to 17% post re-evaluation. AI disruption accelerating. Capital better deployed in Tier A compounders (BYIT.L QS 81). Earnings Feb 26 not waited for."
    exit_reason: capital_rotation_to_tier_a
    lesson_learned: "Tier C positions with high MoS but ROIC < WACC and structural disruption risk should be rotated to Tier A when opportunities arise. MoS alone does not compensate for quality deficit."

  - ticker: LIGHT.AS
    name: "Signify NV"
    entry_date: 2026-01-31
    exit_date: 2026-02-07
    shares: 28.753048
    entry_price_eur: 17.91  # Avg cost
    exit_price_eur: 20.06
    entry_currency: EUR
    invested_eur: 507  # ~597.70 USD / 1.179
    proceeds_eur: 577
    pnl_amount_eur: 70
    pnl_percent: 13.7
    holding_days: 7
    thesis_fv_at_entry: 26.73  # EUR - original
    thesis_fv_v3: 21.90  # EUR - v3.0 re-evaluation post Q4 miss
    fv_reached: false
    quality_score: 56  # Tier B
    thesis_accuracy:
      correct: false
      notes: "Original FV EUR 26.73 was overoptimistic. v3.0 revised to EUR 21.90 post Q4 miss (-17% EPS). Thesis debilitated 2/3 pillars (revenue stabilization failed, ROIC < WACC persistent). On probation awaiting CMD June 23. Took profits (+13.7%) and rotated capital to Tier A (BYIT.L)."
    exit_reason: capital_rotation_to_tier_a
    lesson_learned: "Take profits when thesis weakens materially even if position is small. Probation status with thin MoS (8.4%) and ROIC < WACC is not worth waiting for a catalyst 4.5 months away when Tier A opportunities exist now."

  - ticker: PFE
    name: "Pfizer Inc."
    entry_date: 2026-01-27
    exit_date: 2026-02-07
    shares: 18.66368
    entry_price_usd: 26.75  # Avg cost
    exit_price_usd: 27.22
    entry_currency: USD
    invested_eur: 423  # ~499.25 USD / 1.179
    proceeds_eur: 431
    pnl_amount_eur: 8
    pnl_percent: 1.8
    holding_days: 11
    thesis_fv_at_entry: 32.00  # USD - original
    thesis_fv_v2: 27.74  # USD - v2.0 re-evaluation
    fv_reached: false
    quality_score: 47  # Tier C (estimated, was 49 in system)
    thesis_accuracy:
      correct: false
      notes: "Original FV $32-35 was overestimated (P/E method without WACC derivation). v2.0 revised to $27.74 using DCF+DDM. At $27.22 exit, stock was near fair value (MoS -3.2% = slightly overvalued). ROIC 7% < WACC 8%. Patent cliff 2026-28 structural risk. Capital rotated to Tier A (BYIT.L)."
    exit_reason: capital_rotation_to_tier_a
    lesson_learned: "Positions near fair value with ROIC < WACC and structural headwinds (patent cliff) should be rotated when Tier A opportunities arise. Yield alone (6.5%) does not justify holding when quality is Tier C and MoS is negative."

  - ticker: A2A.MI
    name: "A2A S.p.A."
    entry_date: 2026-02-02
    exit_date: 2026-02-08
    shares: 134
    entry_price_eur: 3.02  # Avg cost in USD, ~EUR 2.56
    exit_price_eur: 2.54
    entry_currency: EUR
    invested_eur: 343  # ~$404.65 / 1.18
    proceeds_eur: 340
    pnl_amount_eur: -5
    pnl_percent: -1.5
    holding_days: 6
    thesis_fv_at_entry: 3.62  # EUR - original thesis v1.0
    thesis_fv_v2: 2.70  # EUR - v2.0 re-evaluation
    thesis_fv_adversarial: 2.04  # EUR - adversarial independent valuation
    fv_reached: false
    quality_score: 37  # Tier C (thesis claimed Tier A, WRONG)
    thesis_accuracy:
      correct: false
      notes: "Original FV EUR 3.62 was inflated 78% vs adversarial EUR 2.04. v2.0 FV EUR 2.70 still inflated 32%. Thesis self-assigned Tier A but QS=37 (Tier C). ROIC spread -3.0pp (destroying value). EBIT overstated 25% (EUR 1,500M vs actual EUR 1,200M). MoS was -24.5% vs adversarial FV. AGCM antitrust probe, net debt +24% in FY2024, 3% annual margin compression all missed by thesis."
    exit_reason: adversarial_review_roic_below_wacc
    lesson_learned: "Thesis FVs systematically inflated ~24%. ROIC < WACC = exit signal. Thesis self-assigned quality tier MUST match quality_scorer.py. EBIT in valuation must cross-check against actual/guided numbers. DDM unreliable when FCF is negative (dividends funded by borrowing)."

  - ticker: VNA.DE
    name: "Vonovia SE"
    entry_date: 2026-02-02
    exit_date: 2026-02-08
    shares: 16
    entry_price_eur: 24.70  # Avg cost ~$29.10 / 1.178
    exit_price_eur: 24.78
    entry_currency: EUR
    invested_eur: 395  # ~$465.56 / 1.179
    proceeds_eur: 396
    pnl_amount_eur: 0
    pnl_percent: 0
    holding_days: 6
    thesis_fv_at_entry: 35.00  # EUR - original v1.0 range midpoint
    thesis_fv_v2: 32.58  # EUR - v2.0 re-evaluation
    thesis_fv_adversarial: 24.35  # EUR - adversarial independent valuation
    fv_reached: false
    quality_score: 41  # Tier C (thesis claimed Tier B, WRONG)
    thesis_accuracy:
      correct: false
      notes: "Original FV EUR 35-38 was inflated ~45% vs adversarial EUR 24.35. v2.0 FV EUR 32.58 still inflated 34%. Thesis used 20% NAV haircut when 35% appropriate (3+ years persistent sector discount). ROIC spread -6.6pp (destroying value). Refinancing wall EUR 10.2B in 2026-2027 not analyzed. Rf stale (2.3% vs actual 2.85% Bund). Interest coverage narrowing to ~2x by 2028. Zero margin of safety vs adversarial FV."
    exit_reason: adversarial_review_roic_below_wacc
    lesson_learned: "For leveraged REITs: NAV haircut must reflect persistent market discount, not aspirational recovery. ROIC < WACC applies to REITs too despite accounting differences. Debt maturity analysis is MANDATORY for leveraged companies. Rf must be current, not stale."

  - ticker: SAN.PA
    name: "Sanofi SA"
    entry_date: 2026-01-31
    exit_date: 2026-02-09
    shares: 5.39
    entry_price_eur: 79.20  # Avg cost
    exit_price_eur: 80.29
    entry_currency: EUR
    invested_eur: 428  # ~$506.23 / 1.183
    proceeds_eur: 433
    pnl_amount_eur: -4
    pnl_percent: -0.84
    holding_days: 9
    thesis_fv_at_entry: 122.02  # EUR - original thesis v2.0
    thesis_fv_adversarial: 78.69  # EUR - adversarial valuation v3.0
    fv_reached: false
    quality_score: 59  # Tool score (adjusted 55). Tier B low-end.
    thesis_accuracy:
      correct: false
      notes: "Original FV EUR 122 inflated 55% vs adversarial EUR 79. Key driver: Amlitelimab Phase III inferior to Dupixent (COAST 2 EU failed). Pipeline failure rate ~50-55%. CFO admitted Dupixent gap too big for internal pipeline. UBS downgrade to Neutral, PT EUR 88. ROIC < WACC (-2.1pp). FV Bridge: 51% FCF growth cut, 32% DDM growth cut, 17% WACC increase. 95% fundamental deterioration, 5% sentiment."
    exit_reason: adversarial_review_roic_below_wacc
    lesson_learned: "8th ROIC<WACC exit. Pharma pipeline risk can destroy 35% of FV in weeks. When CFO admits the problem, thesis is fundamentally broken. MoS evaporation from 34% to 0% validates adversarial approach. NVO (QS 82) provides superior pharma exposure."

  - ticker: HRB
    name: "H&R Block Inc."
    entry_date: 2026-02-03
    exit_date: 2026-02-09
    shares: 31  # 19 original + 10 ADD + 2 fractional (per eToro)
    entry_price_usd: 35.78  # Avg cost (original tranche)
    exit_price_usd: 32.77
    entry_currency: USD
    invested_eur: 576  # ~$679.80 / 1.18
    proceeds_eur: 861  # ~$1,016 / 1.18
    pnl_amount_usd: -155
    pnl_percent: -13.25
    holding_days: 6
    thesis_fv_at_entry: 57.00  # USD - original thesis
    thesis_fv_adversarial: null  # Full adversarial not completed, counter-analysis only
    fv_reached: false
    quality_score: 70  # Tier B
    thesis_accuracy:
      correct: false
      notes: "Counter-analysis scored 18/24 STRONG against thesis. Intuit 600 Expert Offices + $100M OpenAI = two-front moat breach (physical + AI). FCF structural decline: $752M→$657M→$599M→$579M TTM (-23% 3yr). $413M buyback while FCF declining = value destruction. IRS Direct File killed (positive) but Intuit physical expansion is much larger threat. ADD at $35 amplified loss from -4.9% to -13.25%."
    exit_reason: adversarial_review_moat_breach
    lesson_learned: "ADD standing orders for non-Tier-A positions are dangerous - they amplify losses when thesis is subsequently invalidated. Counter-analysis 18/24 STRONG is decisive. Competitive moat breach (physical + AI two-front) is more material than regulatory risk (Direct File)."

  - ticker: IMB.L
    name: "Imperial Brands plc"
    entry_date: 2026-01-31
    exit_date: 2026-02-10
    shares: 14.255583
    entry_price_gbp: 3066  # Avg cost
    exit_price_gbp: 3278
    entry_currency: GBp
    invested_eur: 508  # ~$600 / 1.18
    proceeds_eur: 537
    pnl_amount_eur: 29
    pnl_percent: 6.9
    holding_days: 10
    thesis_fv_at_entry: 3701  # GBp - original thesis v2.0
    thesis_fv_adversarial: 3409  # GBp - adversarial review (Feb 8)
    thesis_fv_v3: 2796  # GBp - v3.0 thesis (Feb 10)
    fv_reached: false
    quality_score: 54  # Tier C (thesis claimed Tier A 9.5/10, WRONG)
    thesis_accuracy:
      correct: false
      notes: "Original FV 3,701 GBp inflated 33% vs v3.0 FV 2,796 GBp. Thesis self-assigned Tier A (9.5/10 custom scale) but QS tool = 54 Tier C. Key gaps not in thesis: $400M HMRC excise tax payment, UK generational tobacco ban confirmed, dividend cut history (2016). MoS was -14.6% at exit (OVERVALUED vs v3.0 FV). Adversarial review (Feb 8) had already flagged as 'next rotation candidate'. Revenue growth is pricing-driven (excise pass-through), not volume — volumes declining 5-8%/yr structurally."
    exit_reason: adversarial_review_overvalued
    lesson_learned: "Excise tax pass-through inflates revenue but distorts quality metrics. Tobacco companies need REIT-like adjusted QS. Thesis self-assigned Tier A was worst misgrade in portfolio (54 vs claimed ~95). Always run quality_scorer.py BEFORE writing thesis, not after. Dividend cut history is a red flag regardless of current yield."

  - ticker: TATE.L
    name: "Tate & Lyle plc"
    entry_date: 2026-02-03
    exit_date: 2026-02-08
    shares: 66
    entry_price_gbp: 378  # Avg cost ~$5.15 = ~378 GBp at time
    exit_price_gbp: 393.60
    entry_currency: GBp
    invested_eur: 288  # ~$339.73 / 1.18
    proceeds_eur: 298
    pnl_amount_eur: 10
    pnl_percent: 3.5
    holding_days: 5
    thesis_fv_at_entry: 551  # GBp - thesis v2.0
    thesis_fv_adversarial: 329  # GBp - adversarial valuation report (base case)
    fv_reached: false
    quality_score: 45  # Tier C (thesis claimed Tier B 5/10 on custom scale)
    thesis_accuracy:
      correct: false
      notes: "Thesis FV 551 GBp inflated by ~40% vs adversarial 329 GBp. Key errors: D&A assumed 100M vs actual 172M (overstated EBIT 23%), EV/EBIT multiple 11x too high vs INGR peer 8.3x, QS miscategorized as Tier B (tool gives Tier C 45/100). ROIC spread -0.5pp per tool (below WACC). Sucralose regulatory risk (WHO/HHS/Tyson) underweighted. Bear case 195 GBp provided zero downside protection at 394 GBp entry."
    exit_reason: adversarial_review_roic_below_wacc
    lesson_learned: "D&A assumptions MUST be cross-checked against actual EBITDA-to-EBIT bridge in results. Post-acquisition D&A (intangible amortization) can be dramatically higher than pre-acquisition baseline. EV/EBIT multiples must anchor to actual peer trading levels, not theoretical ranges. For leveraged mid-caps, EV/EBIT is more reliable than DCF (which had 76% terminal value dependency)."

# Partial Sells (Trims) - Not full exits, but record for P&L tracking
partial_sells:
  - ticker: SHEL.L
    date: 2026-01-31
    shares_sold: 20
    shares_remaining: 20.85
    price_gbx: 2689
    proceeds_approx_eur: 285.00
    pnl_approx_eur: 285.00
    reason: "TRIM - Position 23.9% exceeded 7% max limit"

  - ticker: SHEL.L
    date: 2026-02-02
    shares_sold: 10
    shares_remaining: 10.85
    price_gbx: 2700  # Approx
    proceeds_approx_eur: 150.00
    pnl_approx_eur: 50.00
    reason: "TRIM 2 - Continued rebalancing from 20.85 to 10.85 shares"
    # FINAL EXIT: 2026-02-06 sold remaining 10.85 shares @ 2774.50 GBp - see closed_positions

  - ticker: DTE.DE
    date: 2026-02-03
    shares_sold: 14
    shares_remaining: 23.62
    total_usd: 396.96
    pnl_approx_eur: 70.00  # Estimated gain
    reason: "TRIM - Position 11.3% exceeded 7% max limit"

# Statistics (auto-calculated by effectiveness_tracker.py)
statistics:
  # Will be populated by the tool
  total_closed_positions: 12
  total_partial_sells: 3
  total_realized_pnl_eur: 337.00  # Previous 308 + IMB.L +29 = ~337
  winners: 5  # SHEL.L +2.3%, LIGHT.AS +13.7%, PFE +1.8%, TATE.L +3.5%, IMB.L +6.9%
  losers: 5  # FUTR.L -2.8%, TEP.PA -6.7%, A2A.MI -1.5%, SAN.PA -0.84%, HRB -13.25%
  breakeven: 2  # ENEL.MI 0%, VNA.DE 0%
  win_rate_pct: 41.7
  avg_win_pct: 5.6  # (2.3 + 13.7 + 1.8 + 3.5 + 6.9) / 5
  avg_loss_pct: -4.9  # (-2.8 + -6.7 + -1.5 + -0.84 + -13.25) / 5
  avg_holding_days: 7
  positions_reached_fv: 0
  thesis_accuracy_rate: null
